UPDATE: Piper Jaffray Upgrades Osiris Therapeutics to Overweight on Strong Biosurgery Growth

Piper Jaffray upgraded Osiris Therapeutics OSIR from Neutral to Overweight and maintained a $11.50 price target. Piper Jaffray commented, "Osiris is blowing the doors off Biosurgery sales: up 284% yr/yr and 36% sequentially to $2.9 million in 4Q:12 and totaling $7.8 million for 2012. We now forecast Biosurgery sales growth of 123% to $17.5 million this year. Based on this robust growth, we are upgrading Osiris to Overweight and maintaining our $11.50 price target. Keep in mind that Osiris regained full rights to Prochymal from Genzyme/Sanofi and is now free to sign a new global licensing partnership." Osiris Therapeutics closed at $6.91 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorUpgradesAnalyst RatingsPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!